- Michael Aschner, Vanderbilt University
- Phil Biggin, University of Oxford
- Lucio Guido Costa, University of Washington
- David H Farb, Boston University School of Medicine
- Giorgio Palu, University of Padova
- Christopher Morrey, BioMed Central
MTT assays and trypan blue staining indicate that dipyrithione has novel cytotoxicity, potent broad-spectrum antitumor activity and suggest that it may have potential as an anticancer drug.
Analysis of the pharmacokinetic profile of 1,3-dimethylamylamine (DMAA) in men highlights the relatively low plasma concentrations corresponding to the 25 mg oral dose, and the lack of meaningful physiologic effects associated with a single dose.
The integration of exposure assessment, basic toxicology and models to investigate effective interventions that mitigate or reverse adverse effects of environmental exposures may represent an effective portfolio to improve health by minimizing exposure and producing specific therapeutics.
The ability of nebivolol to stimulate nitric oxide release appears to be independent of its selective beta1-adrenoceptor blockade properties and dependent on stimulation of beta3-adrenoceptors and ATP-mediated stimulation of P2Y-purinergic receptors in human endothelial cells.
Section Editor David Farb provides his insights on recent developments in the field of pharmacology and discusses his future aspirations for BMC Pharmacology and Toxicology.
Polycomblike protein PHF1b stimulates GABRB1 promoter activity in primary cultured neurons and chronic GABA exposure regulates PHF1 binding to endogenous Gabrb1 indicating its role as a molecular transducer of GABA-mediated neurotransmission.
Marta Sidoryk-Wegrzynowicz and Michael AschnerBMC Pharmacology and Toxicology 2013, 14:23 (18 April 2013)
BMC Pharmacology and Toxicology 2013, 14:58
News from the web
- 06 December 2013
- Research & Development for Diseases of the Poor: A 10-Year Analysis of Impact of the DNDi Model
- 04 December 2013
- Lead attorney in US-based Thalidomide cases responds to recent $81 million settlement for Australian victims
- 04 December 2013
- New method for determining structure of key cellular receptors could speed drug development
- 03 December 2013
- Light shed on inconsistencies between large pharmacogenomic studies
BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials.
It is journal policy to publish work deemed by peer reviewers to be a coherent and sound addition to scientific knowledge and to put less emphasis on interest levels, provided that the research constitutes a useful contribution to the field.
Section Editor's profile
David H Farb is Professor and Chair of the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine. He is Principal Investigator and Director of the Laboratory of Molecular Neurobiology and Director of the university-wide NIGMS training program in Biomolecular Pharmacology. A renowned neuropharmacologist, his research integrates existing electrophysiological, behavioral, pharmacological, and molecular genetic technologies in a novel systems-level platform to establish a molecular dissection of spatial memory. Dr Farb is Section Editor for 'Basic pharmacology' and you can read more about the key issues in this field and his aspirations for the journal in his recent interview here.
"Pharmacology is a powerful interdisciplinary science providing an essential link between hypotheses developed from molecular, systems, and clinical models with the ultimate goal of improving human health. Our journal publishes timely research describing advances in a broad range of disciplines that combine novel approaches within a framework of rigorous scientific research."
Join the Editorial Board!
Are you interested in becoming an Editorial Board member for BMC Pharmacology and Toxicology and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor, please simply contact us at firstname.lastname@example.org, enclosing a summary of your research interests and relevant expertise. We look forward to hearing from you.
BMC series blog
- 03 December 2013
- Highlights of the BMC-series: November 2013
- 20 November 2013
- APHA: For science. For action. For health.
- 18 November 2013
- BMC Geriatrics at the 2013 BGS Autumn Scientific Meeting
BMC Pharmacology and Toxicology assimilated the Editorial boards and history of BMC Pharmacology and BMC Clinical Pharmacology on fusion of the journals in 2012. The full archive of BMC Pharmacology is available from its own archive website, and the objectives and aspirations of the merged journal are explained in the editorial that accompanied the fusion. The full archive of BMC Clinical Pharmacology is available here.